Philips introduces SmartIQ to address the trade-off between image quality and radiation dose in coronary procedures

May 18, 2026      Greater differentiation of clinical details through contrast-rich images with reduced background noise​ For coronary procedures, a new ultra-low dose protocol employs over 50% less X-ray radiation dose [1] First SmartIQ clinical pilot study published in JSCAI, further building on Philips' strong track record in evidence generation [2] Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced Philips SmartIQ, a breakthrough coronary imaging technology for its Azurion image-guided therapy. Developed in collaboration with leading cardiovascular centers, SmartIQ is designed to address one of the field's most fundamental challenges: the trade-off between image quality and radiation exposure for patients and clinical staff.